Table 4: Safety of ADA/ETA treatment in groups.

Type of Adverse Events ADA Patients without Uveitis (n=12, 14.5 Patient-Years) ADA Patients with Uveitis (n=13, 27.75 Patient-Years) ETA Patients (n=49, 75.25 Patient-Years)
Infectious AEs, rate 13.8 per 100 patient-years 51.4 per 100 patient-years 39.9 per 100 patient-years
      Acute respiratory virus infection 0 11 25
      Acute bronchitis 0 1 1
      Blepharitis 1 0 0
      Streptococcal pyoderma 1 0 0
      Rotavirus-induced diarrhea 0 1 0
      Urinary tract infections 0 1 0
      Herpes zoster 0 0 1
      Sinusitis 0 0 1
Non-infectious AEs, rate 34.5 per 100 patient-years 7.3 per 100 patient-years 6.6 per 100 patient-years
      Femoral fracture 3* 0 0
      Nasal hemorrhage 1 0 0
      Thrombocytopenia 1 0 0
      Injection site pain 0 1 0
      Hemorrhagic rash 0 1 0
      Allergic reaction 0 0 1
      Elevated transaminase level 0 0 2
      Neutropenia 0 0 2

* only one case was classified as possibly related to the ADA+MTX treatment.